/BVS

BVS Stock - Bioventus Inc.

Q: What is the analyst price target for BVS?

Analyst price target information is not currently available for BVS.

Q: What is BVS's market cap?

Market capitalization information is not currently available for BVS.

Healthcare|Medical - Devices|NASDAQ

$7.49-2.73%

$0.21 (-2.73%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+100.3%upside

Target: $15.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BVS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.79

52W High$11.25

52W Low$5.81

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$573.28M	$512.35M	$512.12M	$430.90M	$321.16M
Gross Profit	$388.23M	$328.19M	$331.08M	$302.71M	$233.52M
Gross Margin	67.7%	64.1%	64.6%	70.3%	72.7%
Operating Income	$-11,979,000	$-81,725,000	$-167,234,000	$12.06M	$21.24M
Net Income	$-33,542,000	$-156,230,000	$-158,704,000	$19.38M	$16.41M
Net Margin	-5.9%	-30.5%	-31.0%	4.5%	5.1%
EPS	$-0.52	$-2.49	$-2.59	$-0.15	$0.44

Company Overview

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

40%

Hold / Neutral

60%

Sell / Underperform

Analyst Consensus🔴 Bearish

2 Bullish3 Neutral/Bearish

Price Targets

Average Target

↑ 17.5% Upside

Now

Low

Average

$13

High

Based on 5 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
July 7th 2025	Cantor Fitzgerald	Initiation	Overweight	$12
December 17th 2024	JP Morgan	Upgrade	Neutral	$13← $12
December 7th 2023	Canaccord Genuity	Upgrade	Buy	$7
August 9th 2023	Craig Hallum	Upgrade	Buy	$6← $4
November 22nd 2022	Craig Hallum	Downgrade	Hold	-
November 9th 2022	Canaccord Genuity	Downgrade	Hold	$6← $18
November 9th 2022	JP Morgan	Downgrade	Underweight	-

Earnings History & Surprises

BVS

Beat Rate

50%

Last 18 quarters

Avg Surprise

+32.4%

EPS vs Estimate

Beats / Misses

9/8

1 met exactly

Latest EPS

$0.15

Q4 2025

EPS Surprise History

Q1 24

+16.7%

$0.07vs$0.06

Q2 24

+240.0%

$0.07vs$-0.05

Q3 24

+171.4%

$0.19vs$0.07

Q4 24

0.0%

$0.06vs$0.06

Q1 25

+87.5%

$0.15vs$0.08

Q2 25

+33.3%

$0.08vs$0.06

Q3 25

-4.5%

$0.21vs$0.22

Q4 25

-30.2%

$0.15vs$0.21

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 4, 2026	—	—	—	—
Q1 2026	Mar 10, 2026	—	—	—	—
Q4 2025	Nov 4, 2025	$0.21	$0.15	-30.2%	✗ MISS
Q3 2025	Aug 6, 2025	$0.22	$0.21	-4.5%	✗ MISS
Q2 2025	May 6, 2025	$0.06	$0.08	+33.3%	✓ BEAT
Q1 2025	Mar 11, 2025	$0.08	$0.15	+87.5%	✓ BEAT
Q4 2024	Nov 5, 2024	$0.06	$0.06	0.0%	= MET
Q3 2024	Aug 6, 2024	$0.07	$0.19	+171.4%	✓ BEAT
Q2 2024	May 7, 2024	$-0.05	$0.07	+240.0%	✓ BEAT
Q1 2024	Mar 12, 2024	$0.06	$0.07	+16.7%	✓ BEAT
Q4 2023	Nov 7, 2023	$0.06	$0.05	-16.7%	✗ MISS
Q3 2023	Aug 8, 2023	$0.03	$0.14	+366.7%	✓ BEAT
Q2 2023	May 16, 2023	$-0.11	$-0.26	-136.4%	✗ MISS
Q1 2023	Mar 31, 2023	$0.05	$-0.06	-220.0%	✗ MISS
Q4 2022	Nov 21, 2022	$0.13	$0.05	-61.5%	✗ MISS
Q3 2022	Aug 11, 2022	$0.14	$0.10	-28.6%	✗ MISS
Q2 2022	May 10, 2022	$0.05	$0.04	-16.7%	✗ MISS
Q1 2022	Mar 10, 2022	$0.20	$0.26	+30.0%	✓ BEAT
Q4 2021	Nov 9, 2021	$0.13	$0.25	+92.3%	✓ BEAT
Q3 2021	Aug 10, 2021	$0.10	$0.16	+60.0%	✓ BEAT